Article Details

Amgen And Kyowa Kirin Present Positive Late-Breaking Data From Phase 2 Study Of AMG ...

Retrieved on: 2021-10-02 09:56:15

Tags for this article:

Click the tags to see associated articles and topics

Amgen And Kyowa Kirin Present Positive Late-Breaking Data From Phase 2 Study Of AMG .... View article details on hiswai:

Excerpt

AMG 451/KHK4083 is a potential first-in-class anti-OX40 fully human monoclonal antibody in development for the treatment of moderate-to-severe atopic ...

Article found on: www.nbc15.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up